Abstract
Background
Sympathetic overstimulation of Müller’s muscle is a suggested mechanism underlying upper eyelid retraction in thyroid eye disease (TED). We examined the effect of tamsulosin, an alpha-1 antagonist, on eyelid retraction in patients with TED.
Methods
A single-centre prospective study. Patients with TED and associated eyelid retraction were treated with oral 0.4 mg/day tamsulosin for 3 months. Upper eyelid margins-to-reflex distance (MRD1), vertical palpebral fissure height (PFH), subjective improvement, signs and symptoms of dry eye, and lubricants use were assessed at baseline and at each subsequent visit.
Results
Eleven suitable patients (mean age 47.5 ± 9.68, 8 females) enrolled in the study. Three patients discontinued the drug due to mild adverse effects (dizziness, bradycardia, nausea, and gastrointestinal distress), which resolved immediately upon stopping treatment. The other eight patients tolerated the drug well and reported no side effects. Five patients experienced an objective improvement in eyelid position and subjective improvement in eye discomfort. The mean MRD1 decreased by −1.04 ± 0.81 mm (P = 0.015), and mean PFH decreased by −1.46 ± 1.33 mm (P = 0.039). Mean duration of tamsulosin treatment was 84.63 ± 71.9 days. Patients discontinued the drug due to no improvement in MRD1 (n = 3), referral for eyelid surgery with stable inactive TED (n = 2), treatment with intravenous methylprednisolone due to worsening active TED (n = 2), and patient choice after 5 months of treatment with spontaneous resolution of symptoms (n = 1).
Conclusions
Tamsulosin is a safe potential treatment for eyelid retraction in TED and can be used as a temporary alternative therapeutic approach for patients unsuitable for surgery.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Data availability
Data are available upon reasonable request.
References
Jain AP, Jaru-Ampornpan P, Douglas RS. Thyroid eye disease: redefining its management—a review. Clin Exp Ophthalmol. 2021;49:203–11.
Lee DC, Young SM, Kim YD, Woo KI. Course of upper eyelid retraction in thyroid eye disease. Br J Ophthalmol. 2020;104:254–9.
Dutton JJ. Anatomic considerations in thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34:S7–12.
Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves’ Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185:G43–67.
Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007;9:181.
Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol. 2016;48:134.
Kaplan SA, Chughtai BI. Safety of tamsulosin: a systematic review of randomized trials with a focus on women and children. Drug Saf. 2018;41:835–42.
Leshno A, Smadar L, Kapelushnik N, Serlin T, Prat D, Priel A, et al. New insight into the physiologic function of Müller’s muscle. Exp Eye Res. 2021;202:108336.
Rüfer F, Schröder A, Erb C. White-to-white corneal diameter: normal values in healthy humans obtained with the Orbscan II topography system. Cornea 2005;24:259–61.
Putterman AM. Margin reflex distance (MRD) 1, 2, and 3. Ophthalmic Plast Reconstr Surg. 2012;28:308–11.
Wiersinga WM. Quality of life in Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:359–70.
Simmons BA, Tran C, Pham CM, Shriver EM. The effect of teprotumumab on eyelid position in patients with thyroid eye disease. Plast Reconstr Surg Glob Open. 2022;10:E4287.
Morgenstern KE, Evanchan J, Foster JA, Cahill KV, Burns JA, Holck DE, et al. Botulinum toxin type a for dysthyroid upper eyelid retraction. Ophthalmic Plast Reconstr Surg. 2004;20:181–5.
Mancini R, Khadavi NM, Goldberg RA. Nonsurgical management of upper eyelid margin asymmetry using hyaluronic acid gel filler. Ophthalmic Plast Reconstr Surg. 2011;27:1–3.
Osaki T, Monteiro L, Osaki M. Management of eyelid retraction related to thyroid eye disease. Taiwan J Ophthalmol. 2022;12:12.
Young SM, Kim YD, Lang SS, Woo KI. Transconjunctival triamcinolone injection for upper lid retraction in thyroid eye disease-a new injection method. Ophthalmic Plast Reconstr Surg. 2018;34:587–93.
Xu D, Liu Y, Xu H, Li H. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy. Can J Ophthalmol. 2012;47:34–41.
Author information
Authors and Affiliations
Contributions
RA—analysing data, writing, editing, and reviewing the protocol and article. HG—extracting and analysing data. GBS, AP, OZ—examining patients, extracting data, and editing the manuscript. DL, TCY, NAL—extracting data and editing the manuscript, OS—study planning, analysing data, examining patients, and critical review of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Arnon, R., Goldberg, H., Ben-Simon, G.J. et al. Alpha-1 antagonist treatment for eyelid retraction in patients with thyroid eye disease—a prospective pilot study. Eye 39, 175–178 (2025). https://doi.org/10.1038/s41433-024-03403-8
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-024-03403-8
